BioMed Research International / 2018 / Article / Tab 1

Research Article

Monitoring Anti-NS1 Antibodies in West Nile Virus-Infected and Vaccinated Horses

Table 1

Details of the horse serum samples used in this study.

WNV strain or vaccineSample group numberInfection modeNº  of serum samplesNº  of animalsdpi/dpvSource/originConfirmatory test

Experimental
Israel ’98 (L1)A1Experimental810-58FranceIgG,IgM,VNT
Austria ’08 (L2)A1Experimental810-58FranceIgG,IgM,VNT
Equip B1Vaccine (experimental)5050-115Spain
Field
UnknownA2Natural2222FranceIgG, IgM
''A3Natural1717ItalyIgM
''A4Natural2424Morocco IgM,IgG
''A5Natural5252SpainIgM, VNT
Equip B2Vaccine2626Spain
Proteq WNV B3Vaccine3030Spain
Proteq WNVB4Vaccine7676Spain
WNVVaB5Vaccine1313Morocco
Recombite + WNVacB6Vaccine1919Morocco
NoneCField (no exposure to WNV)9696Spain

a. Duvaxyne WNV (called now Equip WNV) commercially available by Zoetis. Inactivated WNV, strain VM-2 injectable. Administration route 2 doses IM/annual recalled.
b. Proteq WNV commercially available by Merial. Recombinant virus canary pox containing PrM-E WNV proteins. Administration route 2 doses IM/annual recalled.
c. WNV Vac commercially available by Biopharma. Inactivated WNV, strain Maroc 96-107 injectable. Administration route 2 doses IM/annual recalled.
d. Recombitek equine WNV. The same vaccine as Proteq WNV (b) but lyophilized presentation.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.